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Abstract
Tetradecylthioacetic acid (TTA) is a hypolipidemic antioxidant with immunomodulating properties involving activation
of peroxisome proliferator-activated receptors (PPARs) and proliferation of mitochondria. This study aimed to
penetrate the effect of TTA on the development of atherosclerotic lesions in apolipoprotein (apo)-E-/- mice fed a high-
fat diet containing 0.3% TTA for 12 weeks. These mice displayed a significantly less atherosclerotic development vs
control. Plasma cholesterol was increased by TTA administration and triacylglycerol (TAG) levels in plasma and liver
were decreased by TTA supplementation, the latter, probably due to increased mitochondrial fatty acid oxidation and
reduced lipogenesis. TTA administration also changed the fatty acid composition in the heart, and the amount of
arachidonic acid (ARA) and eicosapentaenoic acid (EPA) was reduced and increased, respectively. The heart mRNA
expression of inducible nitric oxidase (NOS)-2 was decreased in TTA-treated mice, whereas the mRNA level of
catalase was increased. Finally, reduced plasma levels of inflammatory mediators as IL-1α, IL-6, IL-17, TNF-α and
IFN-γ were detected in TTA-treated mice. These data show that TTA reduces atherosclerosis in apoE-/- mice and
modulates risk factors related to atherosclerotic disorders. TTA probably acts at both systemic and vascular levels in
a manner independent of changes in plasma cholesterol, and triggers TAG catabolism through improved
mitochondrial function.
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Introduction
Atherosclerosis is a complex vascular disease with a
bidirectional interaction between lipids and inflammation as a
major feature. These interactions involve monocytes/
macrophages, T cells, vascular smooth muscle cell (SMC) and
endothelial cells, and in addition to inflammation and lipid
deposition, matrix remodelling is an important characteristic of
the atherosclerotic lesion [1]. The liver, which is a central
regulator of fatty acid and glucose metabolism, is also involved
in an atherosclerosis development and systemic low-grade
inflammation characterizing this disorder, as demonstrated by
the increased subclinical atherosclerosis in patients with non-
alcoholic fatty liver disease (NAFLD) [2]. Additionally, there is
growing evidence supporting a role of mitochondrial
dysfunction that also involves enhanced oxidative stress in the
pathogenesis of atherosclerosis [3,4]. Despite state-of-the-art
cardiovascular treatment including the use of statins, 38% of all
deaths in North America is related to atherosclerosis, and it is
the most common cause of death in European men over 45
and in woman over 65 years of age [5]. The growing epidemic
of obesity and diabetes associated with a metabolic phenotype
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characterized by dyslipidemia may further contribute to an
increased risk of cardiovascular disease. These factors force
us to consider new strategies for prevention and treatment of
atherosclerotic disorders. Although statins have been shown to
possess anti-inflammatory properties, modulation of the non-
resolving inflammation that characterizes the atherosclerotic
process is still a therapeutic challenge.
Tetradecylthioacetic acid (TTA) is a modified saturated fatty
acid (SFA) analogue made of 16 carbons, plus a sulphur atom
inserted in the 3-position from the carboxylic end. Following
cellular uptake, TTA is converted to TTA-CoA [6], which is a
good substrate for the carnitine palmitoyltransferase system
(CPT1 and CPT2) [7], transporting acyl-CoA into the
mitochondria. However, due to the sulphur atom at the 3
position TTA is blocked for β-oxidation [8], and the S-
substitution also contribute to the antioxidant effect [9]. TTA
stimulates mitochondrial fatty acid oxidation of normal β-
oxidizable fatty acids [10] and induces mitochondrial
proliferation in rat hepatocytes [11]. As a pan-ligand for
members of the peroxisome proliferator-activated receptor
(PPAR) family of nuclear hormone receptors, TTA regulates
expression of fatty acid metabolizing enzymes, in particular
those of the catabolic pathway [12–14]. TTA is reported to have
both cholesterol- and triacylglycerol (TAG) lowering effect in in
psoriasis patients [8]. The increased mitochondrial fatty acid
oxidation and mitochondrial proliferation seem to be important
in regulating plasma TAG level [11,12]. Moreover, TTA is an
antioxidant [15] with immunomodulating properties, able to
lower plasma level of tumor necrosis factor (TNF)-α, vascular
cell adhesion molecule (VCAM)-1 and interleukin (IL)-8 in vitro
[16] as well as in vivo [17]. The anti-inflammatory effects of
TTA appear to involve both PPARα-dependent and –
independent pathways [16]. Finally, TTA is found to be present
in the coronary wall [18], suggesting a potential for a direct
effect on coronary atherosclerosis.
Based on its hypolipidemic properties as well as its anti-
oxidative and anti-inflammatory potential involving
mitochondrial related mechanisms, we examined the ability of
TTA to modulate atherosclerotic lesion development through
an intervention study in apolipoprotein E-deficient (apoE-/-)
mice. ApoE-/- mice are a widely recognized model for
hypercholesterolemia that spontaneously develops
atherosclerotic lesions, even on a standard chow diet with low
fat and no cholesterol [19] and have been used to study the




The animal study was conducted according to the national
(D.L. 116, G.U. Suppl. 40, February 18, 1992, Circolare No. 8,
G.U July 1994) and international laws and policies (EEC
Council Directive 86/609, OJL 358, 1, December 12, 1987:
Guide for the Care and Use of Laboratory Animals, United
States National Research Council, 1996). The Italian Ministry
of Health approved the protocol. Mice were kept under
standard laboratory conditions with temperature 22±1°C, dark/
light cycles of 12/12 h, relative humidity 55±5% and 20 air
changes per hour. Food and tap water was given ad libitum.
Twenty-four female apoE -/- mice (North Carolina, Charles
River Laboratories, Italy), 8 weeks old, were randomly divided,
based on body weight, into two groups of 12 animals. Mean
cholesterol levels pre-treatment were not different between
groups (8.16±0.80 vs 7.73±0.62 mmol/L, p=0.429). The control
group was fed a high-fat diet (23.7% w/w) consisting of 21.3%
lard (a generous gift from Ten Kate Vetten BV, Musselkanaal,
Netherlands) and 2.4% soy oil (Dyets. Inc., Betlehem, PA,
USA), with 25% w/w casein (Dyets Inc., Bethlehem, PA, USA)
as protein source, while the intervention diet was
supplemented with 0.3% w/w TTA, and TTA was synthesized
as previously described [21]. The energy contribution from fat,
carbohydrates, and protein were 46.9%, 32.8% and 20.3%,
respectively and the full composition of the diets is given in
Table S1. Mice had free access to tap water and feed during
the 12 weeks of feeding.
Blood and tissue harvesting
Day 0 and after 28, 56 and 77 days of dietary treatment,
blood was collected from the retro-orbital plexus into tubes
containing 0.1% (w/v) EDTA after an overnight fasting. Blood
samples were chilled on ice for at least 15 minutes, centrifuged
and stored at -80°C prior to analysis. After 84 days of
treatment, mice were anesthetized with 2% isoflurane (Forane,
from Abbot Laboratories Ltd, Illinois, USA) and blood was
removed by perfusion with phosphate-buffered saline (PBS).
Aorta was rapidly dissected from the aortic root to the iliac
bifurcation, periadventitial fat was removed and aorta was
pinned flat on a black wax surface in ice-cold PBS and
photographed. After photographing, aorta was immediately put
in a tissue-freezing medium, snap-frozen in liquid nitrogen and
stored at -80°C. For histological/immunohistochemical analysis,
six hearts from each group were removed, fixed in 10%
formalin for 30 min and transferred into PBS containing 20%
sucrose (w/v) overnight at 4°C before being embedded in OCT
compound (Sakura Finetek Euope B.V., Alphen aan den Rijn,
The Netherlands) and stored at -80°C. An equal subset of
hearts was dedicated to qPCR analysis and immediately snap-
frozen in liquid nitrogen. Livers from all animals were
harvested, and a portion was embedded in OCT compound.
The embedded portion and the remaining tissue were snap-
frozen and stored at -80°C until further processing.
En face analysis
Images of the aorta were captured with a stereomicroscope-
dedicated camera (IC80 HD camera, MZ6 microscope, Leica
Microsystems, Germany), and analyzed with ImageJ image
processing program (http://rsb.info.nih.gov/ij/). An operator
blinded to dietary treatment quantified atherosclerosis.
Aortic sinus and liver histology/immunohistochemistry
Serial cryosections (7 μm thick) of the aortic sinus were cut
and stained with hematoxylin and eosin (Bio-Optica, Milano,
Italy) to evaluate plaque area and with Masson’s Trichrome
(04-010802, Bio-Optica, Milano, Italy) to evaluate extracellular
matrix deposition. Oil red O staining was used to detect
Fatty Acid Analogue Effect on Atherosclerosis
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intraplaque neutral lipids (Sigma-Aldrich, St. Louis, MO, USA).
Seven μm thick sections were also cut from the liver and
stained with Red Oil O.
Macrophages and lymphocytes were detected using an anti-
F4/80 antibody (ab6640, Abcam, Cambridge, UK), and an anti-
CD3 antibody (ab16669, Abcam, Cambridge, UK), respectively.
A biotinylated secondary antibody was used for streptavidine-
biotin-complex peroxidase staining (Vectastain Abc Kit, Vector
Laboratories, Peterborough, UK). 3,3’-Diaminobenzidine (DAB)
was used as chromogen (Sigma-Aldrich, St. Louis, MO, USA),
and sections were counterstained with hematoxylin (Gill’s
Hematoxylin, Bio-Optica, Milano, Italy).
The Aperio ScanScope GL Slide Scanner (Aperio
Technologies, Vista, CA, USA), equipped with a Nikon 20x/
0.75 Plan Apochromat objective producing a 0.25 μm/pixel
scanning resolution and the Aperio ImageScope software
(version 8.2.5.1263), was used to acquire and process digital
images with a 40x magnification. An operator blinded to dietary
treatment quantified the plaque area, extracellular matrix and
lipid composition, as well as inflammatory cell infiltrate.
Plasma and liver lipids and fatty acid composition in
heart and plasma
Liver lipids were extracted according to Bligh and Dyer [22],
evaporated under nitrogen, and redissolved in isopropanol
before analysis. Lipids from liver extracts or plasma were then
measured enzymatically on a Hitachi 917 system (Roche
Diagnostics GmbH, Mannheim, Germany) using the TAG
(GPO-PAP), cholesterol (total, free, LDL and HDL) kit (CHOD-
PAP) from Roche Diagnostics, phospholipid kit from
bioMérieux SA (Marcy l'Etoile, France) and non-esterified fatty
acid (NEFA) kit from DiaSys Diagnostic Systems GmbH
(Holzheim, Germany). Total plasma fatty acid composition in
heart and plasma was analyzed as described previously [23].
Hepatic enzyme activities
Livers were homogenized and a post-nuclear fraction made
as described earlier [24]. The activity of carnitine
palmitoyltransferase (CPT)-1 was performed according to
Bremer [25], but with some modifications: the reaction mix
contained 17.5 mM HEPES pH 7.5, 52.5 mM KCl, 5 mM KCN,
100 mM palmitoyl-CoA, and 6.67 mg BSA/mL. 100 μM
[methyl-14C]-L-carnitine (1100 cpm/ηmol) inititated the
reaction, and 30 μg total protein was used. The assay
conditions for CPT-2 were identical except that BSA and KCN
was omitted and 0.01% Triton X-100 was included, and a total
of 35 μg was used.
Acyl-CoA oxidase (ACOX)-1 activity was measured using 20
μg protein, as described by Madsen et al [26].. 3-hydroxy-3-
methylglutaryl coenzyme A synthase (HMG-CoA) were
measured in the post-nuclear fraction as described by Skorve
et al. [27], and citrate synthase activity was measured as
previously described [28].
Gene expression analysis
Total cellular RNA was extracted from liver, homogenates
from the whole heart and from pooled aortic arch segments,
and cDNA was produced as previously described [29].
Quantitative real-time PCR was performed on an ABI prisme
7900 H sequence detection system from Applied Biosystems
with Sarstedt 384 well multiply-PCR Plates (Sarstedt Inc.,
Newton, NC, USA) using probes and primers from Applied
Biosystems. The primers used are listed in Table S2. Six
different reference genes were included for liver and heart, and
three for aorta: 18s (Kit-FAM-TAMRA (Reference RT-
CKFT-18s)) from Eurogentec, Belgium, ribosomal protein,
large, P0 (Rplp0, Gene ID 11837), hypoxanthine guanine
phosphoribosyl transferase 1 (Hprt1, AX-045271-00),
ribosomal protein, large, 32 (Rpl32, AX-055111-00),
polymerase II (DNA directed) polypeptide A, (Polr2a,
AX-046005-00) and TATA-box binding protein (Tbp,
AX-041188-00) from Thermo Fisher Scientific. GeNorm were
used to evaluate the reference genes [30], and data normalized
to Rplp0 and Rpl32 are presented for liver, Hprt1 for heart and
18S, Rplp0 and Hprt1 for aortic arch segment.
Measurements of inflammatory markers
Levels of IL-1α, IL-1β, IL-6, IL-10, IL-17, interferon (IFN)-γ,
monocyte chemoattractant protein (MCP)-1 and TNF-α were
analyzed on plasma samples collected at day 77 after
treatment by Multiplex suspension technology using a
customized Bio-Plex Pro Mouse assay (Bio-Rad Laboratories,
Hercules, CA).
Statistical analysis
Data sets were analyzed using Prism Software (GraphPad
Prism version 5.0; GraphPad Prism, San Diego, CA, USA) to
determine statistical significance. The results are shown as
means of 3 to 12 animals per group with their standard
deviations. Normal distribution was determined by the
Kolmogorov-Smirnov test (with Dallal-Wilkinson-Lilliefors P
value). Unpaired t-test was performed to evaluate statistical
differences between two groups, or Mann Whitney test when
values were not normally distributed. P-values <0.05 were
considered significant.
Results
TTA effects on atherosclerosis development
After treatment, mice fed TTA displayed the same body
weight as controls (Figure 1A). TTA diet administration
significantly inhibited the development of atherosclerotic
lesions at the aortic arch compared with the control diet (Figure
1B). A lower atherosclerotic development was also observed in
TTA-treated mice at the thoracic and abdominal aorta without
reaching statistical significance (Figure 1B). However,
considering the entire aortic surface, TTA-treatment
significantly inhibited atherosclerosis development (0.39 ± 0.22
x 106 μm2 in TTA-mice vs 1.09 ± 0.50 x 106 μm2 in controls;
p=0.016, Figure 1B). In addition, a tendency towards a
decrease in lesion area was observed at the aortic sinus of
TTA mice compared with control mice (1.49 ± 0.30 x 105 μm2
vs. 2.02 ± 0.31 x 105 μm2, respectively; p=0.068; Figure 2A-C).
In contrast to the decrease in lesion size, the histological/
immunohistochemical characterization of atherosclerotic
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lesions did not show any significant difference in plaque
composition between controls and TTA mice, displaying a
comparable percentage of extracellular matrix (30.31 ± 18.25
% vs. 29.75 ± 15.89 %; Figure 2D-F), lipids (79.68 ± 6.45 % vs.
71.17 ± 6.97 %; Figure 2G-I), macrophages (60.47 ± 3.71 %
vs. 57.13 ± 2.75 %; Figure 2J-L) and lymphocytes (22.62 ±
7.24 % vs. 27.26 ± 9.05 %; Figure 2M-O).
TTA effects on genes related to inflammation and
oxidative stress in heart and aorta
Enhanced inflammation and oxidative stress seem to be
recurring factors in atherogenesis. Therefore it was of interest
to observe that the gene expression of inducible nitric oxidase
(Nos2) was significantly decreased in the heart of TTA-treated
apoE-/- mice compared to controls (Figure 3A), whereas gene
expression of the key antioxidant enzyme, catalase (Cat) was
significantly increased (Figure 3B). The mRNA expression of
Vcam1 and intracellular adhesion molecule 1 (Icam1) in the
heart tended to be decreased by TTA administration, but the
differences did not reach statistical significance (Figure 3C, D).
The gene expression of the inflammatory mediators Mcp1 and
Tnfa, and the antioxidants soluble superoxide dismutase
(Sod1) and mitochondrial superoxide dismutase (Sod2) were
unchanged (data not shown). The mean mRNA level of Icam1,
Vcam1 and Mcp1 decreased in pooled aortic arch from six
animals, whereas mRNA Nos2 levels seemed to be unchanged
by the treatment (Figure 3E).
Effect of TTA on systemic inflammation
In addition to its potential anti-inflammatory effect within the
aortic arch, TTA administration decreased plasma levels of
several inflammatory cytokines and chemokines in apoE-/-
mice. As shown in Figure 4, IL-1α, IL-6, IL-17, TNF-α and IFN-γ
levels were significantly lower in TTA-treated mice compared to
controls. IL-6, IL-17, TNF-α and IFN-γ levels significantly and
directly correlated with mouse aortic plaque area (r = 0.70,
p=0.011; r = 0.74, p=0.006; r = 0.68, p=0.015; r = 0.64,
p=0,027, respectively). No significant changes of IL-1β, IL-10,
and MCP-1 could be observed after TTA administration (data
not shown).
Effect of TTA on lipid concentrations in plasma
The plasma concentrations of TAGs and NEFAs were
significantly reduced in the TTA-treated mice compared to the
control group already after 28 days of treatment (Figure 5A, B).
Interestingly, plasma total and free cholesterol levels were
increased (Figure 5C, D), as well as levels of HDL- and LDL-
cholesterol (Figure 5E, F) whereas the plasma phospholipid
concentration and the ratio of HDL/LDL-cholesterol were
unaffected by TTA administration compared to the controls
(data not shown).
Effect of TTA on fatty acid composition in heart and
plasma
Dietary supplementation with 0.3% TTA promoted different
effects on heart and plasma fatty acid composition in apoE-/-
mice fed a high-fat diet (Table 1). While TTA had no effect in
the relative amounts of saturated fatty acids (SFA) in heart, it
reduced the weight % of SFA in plasma, mainly as a
consequence of reduced due amount of stearic acid (C18:0)
(Table 1). In contrast, TTA had no significant effect on the
relative amount of monounsaturated fatty acid in heart or
plasma (Table 1). Δ9 desaturated TTA in addition to TTA was
found in heart and plasma (Table 1) demonstrating an activity
of SCD1. TTA significantly increased the relative amounts of
n-9 polyunsaturated fatty acids (PUFAs) in both heart and
plasma, mainly because of increased relative amounts of mead
acid (C20:3n-9) (Table 1). While TTA induced a decrease in
n-3 PUFAs in plasma, due to decreased relative amounts of
C18:3n-3, C18:4n-3, C20:5n-3 and C22:6n-3, the relative
amounts of n-3 PUFAs tended to increase during TTA
treatment in the heart, due to significantly increased amounts
of EPA (C20:5n-3) and DPA (C22:5 n-3) (Table 1). TTA
decreased the weight % of n-6 PUFAs in heart, mainly
reflecting a reduction in the prostaglandin precursor
arachidonic acid (20:4n-6). TTA increased n-6 PUFAs in
plasma and this was due to increased relative amounts of
C20:3n-6, C20:4n-6 and C22:4n-6 (Table 1). Altogether, TTA
administration for 12 weeks influenced the ratio of n-3 to n-6
PUFAs in two different ways: in heart an increase was
observed, whereas in plasma a reduction was found (Figure
6H).
Hepatic gene and enzyme activities
TTA and delta 9 desaturated TTA were also found in liver of
TTA-treated mice (Figure 6A, B), indicating that TTA-CoA is a
suitable substrate for SCD1. The mRNA level of Scd1,
however, was unchanged by TTA administration (Table 2).
Under normal condition, fatty acids to the liver can either be
oxidized or secreted in the VLDL-particles. Gene expression of
Cd36 was up-regulated in TTA-treated mice (Table 2)
indicating higher influx of fatty acids to the liver. We found that
the activities of both CPT1 and CPT2 were stimulated in the
TTA-fed mice compared to controls (Figure 6C, D,
respectively), in addition to increased HMG-CoA synthase
activity (Figure 6E) demonstrating increased mitochondrial fatty
acid oxidation and ketogenesis. This was also associated with
higher levels of the mitochondrial biomarker citrate synthase
(Figure 6F). Up-regulation of these enzymes, as well as of
ACOX1 (Figure 6G) by TTA administration, supports PPARα
activation. The mRNA expression of Ppara, however, was
unchanged (Table 2). The lipid droplets and the hepatic level of
total TAG were decreased in TTA-treated apoE-/- mice (Figure
6H, I). Hepatic TAG biosynthesis and VLDL secretion seemed
to be unaffected by TTA treatment as the gene expression of
Gpat and ApoB were similar in TTA-treated mice compared to
controls (Table 2). The mRNA expression of VLDL receptor
(VLDLr) was significantly increased (Table 2). Reduced hepatic
TAG content may partly be due to reduced lipogenesis as the
mRNA expression of acetyl carboxylase alpha (Acaca) was
decreased by TTA administration (Table 2).
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Figure 1.  Effects of TTA on body weight and aortic atherosclerosis development apoE-/- mice fed a high-fat diet (control) or
a diet supplemented with 0.3% TTA.  After 12 weeks of diet induction, TTA-fed mice displayed the same growth curve as controls
(A). Whole aorta was collected and en-face analysis was performed to quantify aortic surface covered by atherosclerotic plaques
(B). Data are shown as means ± SD for 6-12 mice for each diet. Unpaired t-test was used to detect statistical significance. *P<0.05
vs. control.
doi: 10.1371/journal.pone.0081963.g001
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Discussion
TTA is reported to be an important regulator of lipids through
PPARs [12,16,31] and to have positive effects on plasma lipid
risk factors related to cardiovascular diseases [32] and most
probably to atherosclerosis [33]. Therefore, the ability of TTA to
inhibit the development of atherosclerosis in apoE-/- mice fed on
a high-fat diet was investigated. Notably, TTA was found to
reduce atherosclerotic plaque area in the aortic arch in these
mice. In addition, a decrease in lesion area was observed at
the aortic sinus of TTA-treated mice, but failed to be significant
possibly due to small sample size. However, our results
suggest a potential beneficial effect of TTA treatment on plague
formation.
The atherosclerotic process is initiated by accumulation of
plasma lipoproteins in the subendothelial space of the blood
vessel and uptake of these lipoproteins by machrophages will
result in their transformation into foam cells [34]. Noteworthy,
the plasma cholesterol, free cholesterol, HDL- and LDL-
cholesterol levels were increased by TTA treatment,
suggesting that effect of TTA on plaque reduction is not related
to its cholesterol lowering properties. Inflammation has
emerged as an important factor in the development of
atherosclerosis characterized by a state of non-resolving
inflammation. In contrast to the lack of effect on plasma
cholesterol, TTA induced a marked decrease in plasma levels
of several inflammatory mediators with relevance to
atherogenesis such as IL-1α, IL-6, IL-17, TNF-α and IFN-γ.
Moreover, TTA also induced a decrease in the gene
expression of Icam1, Vcam1 and Mcp1 within the aortic arch,
suggesting anti-inflammatory effects of TTA both systemically
and within the lesions. Although we have no firm evidence, it is
tempting to hypothesize that the atheroprotective effect of TTA
in apoE-/- mice involves both anti-inflammatory and anti-
oxidative effects of this fatty acid.
Figure 2.  Histological and immunohistochemical characterization of plaques at the aortic sinus in apoE-/- mice fed a high-
fat diet (control) or a diet supplemented with 0.3% TTA for 12 weeks.  Representative photomicrographs and quantification of
maximum plaque area (panels A-C). Representative photomicrographs and quantification of extracellular matrix deposition (panels
D-F), lipid deposition (panels G-I), macrophages (panels J-L) and T lymphocytes (panels M-O). Bar in panel A = 100 μm. Data are
shown as means ± SD for 6 mice for each diet.
doi: 10.1371/journal.pone.0081963.g002
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The effects of TTA on fatty acid composition could also be of
relevance for the effect of TTA on plaque size. Thus, while TTA
treatment resulted in significant increased plasma level of
arachidonic acid (C20:4n-6), the precursor for prostaglandins
[35], and a tendency to reduced amount of the anti-
inflammatory n-3 PUFAs in plasma, TTA increased the amount
of the n-3 PUFAs EPA (C20:5n-3) and DHA (C22:6n-3), and
decreased the amount C20:4n-6 within the heart. We have
previously shown that TTA is taken up in endothelial cells [16]
and macrophages [36], and after local delivery reduces the
local inflammatory responses and collagen accumulation [37].
TTA inhibits proliferation of smooth muscle cells and has the
ability to attenuate TNFα-mediated endothelial cell activity
involving both PPARα-dependent and –independent pathways
[16]. As previously reported, TTA was taken up in the arterial
wall [18]. Thus, its anti-atherosclerotic effect could be a direct
action on the vascular cells with anti-inflammatory and
antioxidative effects, at least partly related to its effect of the
local fatty acid composition.
In normolipidemic rats [38] and chronic inflammatory mice
[39] the plasma levels of TAGs and NEFAs, as well as the
hepatic concentration of TAGs, are regulated by the hepatic
mitochondrial activity after TTA treatment. In the present study,
the increased mRNA level of Cd36, which may be involved in
fatty acid translocase, could result in an increased fatty acid
uptake by the liver. The activation of fatty acids to their CoA -
esters, catalyzed by long-chain acyl-CoA synthetase, is
probably stimulated by TTA administration [39]. Plasma TAG
levels depend on the balance between TAG synthesis,
degradation and catabolism by the liver, as well as on its
intravascular catabolism. We have previously reported that thia
fatty acid treatment resulted in a more pronounced decrease in
plasma TAGs than the decrease VLDL-secretion, indicating
that changes in clearance of VLDL might contribute to the
reduction in plasma TAGs [27]. Indeed, the lipoprotein lipase
Figure 3.  Relative mRNA levels of inflammatory and oxidative stress markers in heart of apoE-/- mice fed a high-fat diet
(control) or a diet supplemented with 0.3% TTA after 12 weeks.  A) Nos2, B) Catalase, C) Icam1, D) Vcam1 and E) Aortic arch.
Bars represent means ± SD for 3-4 mice for each diet. Mann-Whitney test was used to detect statistical significance and results
significantly different from control are indicated **P<0.01.
doi: 10.1371/journal.pone.0081963.g003
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(LPL) mRNA in 3T3-L1 preadipocytes was increased by TTA
[40]. Thus, this LPL action may well result in a decrease of
plasma TAGs in TTA-treated apoE(-/-) mice. The apoE-/- mice
exhibited increased hepatic activities of both CPT1 and CPT2
and a slightly up-regulation of CPT2 could be confirmed at the
mRNA level. Moreover, proliferation of mitochondria and
peroxisomes seemed to take place in the liver of apoE-/- mice
as activities of both citrate synthase and ACOX1 were
increased by TTA supplementation. TTA significantly reduced
the hepatic TAG level in apoE-/- mice and this is most probably
due to increased fatty acid catabolism and decreased
lipogenesis as the gene expression of Acaca was reduced.
Both TTA-treated mice and control mice displayed similar
weight gain during the study, showing that our beneficial effects
of TTA are not simply due to suppression of appetite, lack of
palatability or blockage of intestinal uptake of dietary fatty
acids. Overall, we hypothesize that the triggered TAG
metabolism accompanied with increased mitochondrial function
in liver may contribute to the beneficial action of TTA in apoE-/-
mice.
The present study has some limitations such as the lack of
protein data and lack of data on fatty acid composition within
the lesion. However, our observations suggest that the
modified fatty acid analogue, TTA, inhibits atherosclerosis
development in vivo, an effect most likely independent of
changes in plasma cholesterol levels, but related to an
inflammatory response both at vascular and systemic levels, in
addition to an antioxidant effect at the vascular level. This could
be related to the effect of TTA on local fatty acid composition
as well as its effect on mitochondrial function in the liver.
Forthcoming studies should further explore the mechanism by
which TTA exerts its anti-atherosclerotic effects. If its athero-
protective effects are confirmed in additional studies on
experimental atherosclerosis, TTA should be explored as
treatment modality in clinical atherosclerosis.
Figure 4.  Plasma concentration of inflammatory mediators in apoE-/- mice fed a high-fat diet (control) or a diet
supplemented with 0.3% TTA for 11 weeks.  Blood samples collected at day 77 of treatment were analysed A) IL-1α, B) IL-6, C)
IL-17, D) TNF-α and E) IFN-γ. Bars represent means ± SD for 4 mice for each diet. Unpaired t-test was used to assess statistical
significance and results significantly different from control are indicated *P<0.05, **P<0.01, ***P<0.001.
doi: 10.1371/journal.pone.0081963.g004
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Figure 5.  Plasma lipid concentrations of apoE-/- mice fed a high-fat diet (control) or a diet supplemented with 0.3%
TTA.  After 28, 56 and 77 days of diet induction, blood was collected, EDTA plasma was isolated and plasma lipids were
determined by enzymatic assay. A) Triacylglycerols, B) Non-esterified fatty acids, C) Cholesterol, D) Free cholesterol, E) High-
density lipoprotein cholesterol and F) Low-density lipoprotein cholesterol. Bars represent means ± SD for 4 mice for each diet.
Unpaired t-test was used to detect statistical significance and results significantly different from control are indicated *P<0.05,
**P<0.01, ***P<0.001.
doi: 10.1371/journal.pone.0081963.g005
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Table 1. Fatty acid composition in heart and plasma of
apoE-/- mice fed a high-fat diet (control) or a diet
supplemented with 0.3% TTA for 12 weeks.
Fatty acids Heart Plasma
 Control TTA Control TTA
SFAs 31 ± 0.68 31 ± 0.84 32 ± 0.47 32 ± 0.16
C18:0 16 ± 0.59 16 ± 1.11 12 ± 0.20 8.8 ± 0.20***
C22:0 0.17 ± 0.01 0.20 ± 0.02 0.40 ± 0.02 0.40 ± 0.03**
C23:0 0.05 ± 0.00 0.08 ± 0.01** 0.16 ± 0.02 0.21 ± 0.02**
C24:0 0.09 ± 0.01 0.12 ± 0.01* 0.31 ± 0.02 0.36 ± 0.02*
TTA <0.00 32 ± 0.69* <0.00 33 ± 0.20
MUFAs 21 ± 1.9 18 ± 4.4 31 ± 0.42 29 ± 0.81***
C18:1n-7 2.0 ± 0.05 2.0 ± 0.04 1.3 ± 0.03 1.2 ± 0.04**
n9 PUFAs 0.13 ± 0.00 0.24 ± 0.04* 0.21 ± 0.31 0.41 ± 0.29
C18:1n-9 17 ± 1.7 14 ± 3.7 25 ± 0.38 24 ± 0.77*
C20:3n-9 0.13 ± 0.00 3.2 ± 0.04* 0.2 ± 0.01 0.4 ± 0.03***
TTA:1n-8 <0.00 37 ± 2.4* <0.00 30 ± 0.81
n6 PUFAs 26 ± 0.61 23 ± 1.0* 28 ± 0.37 32 ± 0.82***
C20:3n-6 0.66 ± 0.02 1.2 ± 0.18** 0.5 ± 0.01 1.2 ± 0.04***
C20:4n-6 8.7 ± 0.37 7.0 ± 0.64* 12 ± 0.4 15 ± 0.9***
C22:4n-6 0.77 ± 0.03 0.80 ± 0.11 0.21 ± 0.01 0.28 ± 0.02**
n3 PUFAs 23 ± 1.4 26 ± 4.0 6.4 ± 0.01 5.3 ± 0.10***
C18:3n-3 0.23 ± 0.01 0.20 ± 0.06 0.60 ± 0.09 0.40 ± 0.02**
C18:4n-3 <0.00 <0.00 0.05 ± 0.00 0.01 ± 0.00***
C20:5n-3 0.06 ± 0.00 0.11 ± 0.02* 0.5 ± 0.04 0.3 ± 0.00**
C22:5n-3 1.7 ± 0.08 3.0 ± 0.57* 0.31 ± 0.02 0.35 ± 0.03*
C22:6n-3 21 ± 1.3 23 ± 3.6 5.0 ± 0.3 4.2 ± 0.1**
n3/n6 0.88 ± 0.07 1.1 ± 0.12* 0.23 ± 0.01 0.17 ± 0.01*
Values are given as % (w/w) and shown as means ± SD for 6 mice for each diet.
*P<0.05, **P<0.01, ***P=0.001.
doi: 10.1371/journal.pone.0081963.t001
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Figure 6.  Hepatic paramters in apoE-/- mice fed a high-fat diet (control) or a diet supplemented with 0.3% TTA for 12
weeks.  In liver extracts, fatty acids were measured using gas-liquid chromotography, enzyme activities were measured
spectrophotometrically and lipid deposition was assessed using Red Oil staining. A) Tetradecylthioacetic aicd and B) TTA:1n-8, C)
Carnitine palmitoyltransferase 1a activity, D) carnitine palmitoyltransferase 2 E) 3-hydroxy-3-methylglutaryl coenzyme A synthase
activity F) Citrate synthase activity, G) Acyl-coenzyme A oxidase activity, H) Lipids droplets and I) Triacylglycerols. Bars represent
means ± SD in 4-6 mice for each diet. Unpaired t-test was used to detect statistical significance and results significantly different
from control are indicated *P<0.05, **P<0.01, ***P<0.001.
doi: 10.1371/journal.pone.0081963.g006
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Table 2. Hepatic gene expression om apoE-/- mice after 12
weeks of dietary supplementation.
Lipid transport and β-oxidation Diet groups P value
Gene Function Control TTA  
Apob Fatty acid transport 1.00 ± 0.09 0.87 ± 0.17 0.501
Cd36 Fatty acid import 1.00 ± 0.20 2.23 ± 0.52* 0.045
Cpt1a β-oxidation 1.00 ± 0.27 0.55 ± 0.15 0.252
Cpt2 β-oxidation 1.00 ± 0.04 1.18 ± 0.16 0.260
Vldlr Fatty acid import 1.00 ± 0.11 2.46 ± 0.56* 0.029
Lipogenesis, desaturation and
transcription Diet groups P value
Gene Function Control TTA  
Acaca Fatty acid synthesis 1.00 ± 0.08 0.676 ± 0.03 0.203
Gpat Glycerolipid synthesis 1.00 ± 0.13 1.44 ± 0.14 0.075
Scd1 Desaturation 1.00 ± 0.14 0.72 ± 0.02 0.161
Ppara Energy homeostasis 1.00 ± 0.20 0.68 ± 0.33 0.463
Data are shown as relative values ± SD 4 mice for each diet. *P<0.05.
doi: 10.1371/journal.pone.0081963.t002
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